parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in lymphatic endothelial cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16617

receipt 16625: LAYN in dopamine neurons, braak

power: full sample +0.14 (p 0.567, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.16 (p 0.521, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.627, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.25, sign flips 0; without severely affected donors +0.14 (p 0.567, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LAYN in dopamine neurons.

case closed: nothing better to follow up.

receipt 16624: LAYN in oligodendrocytes, braak

power: full sample -0.29 (p 0.246, n 18), 95% CI -0.67 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.28 (p 0.261, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.29 (p 0.235, n 18). could be the mix.
skeptic: leave-one-out range -0.43 to -0.18, sign flips 0; without severely affected donors -0.29 (p 0.246, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LAYN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts